Evicenter
P&T meetings

Atebrioz (zilurgisertib)

Fibrodysplasia ossificans progressiva

Also known as INCB000928
Regulatory submission
NDA submitted by May 2026
Last updated
96 sources

Economic information and modeling reportBudget impact model

Approach and framework

1 evidence topic · 1 source

Budget impact model of zilurgisertib

No evidence found.

Palovarotene budget impact analysis submitted to CADTH: approach and scenarios compared

“The sponsor’s pan-Canadian estimates reflect the aggregated results from provincial budgets (excluding Quebec), as well as the Non-Insured Health Benefits Program.” (opens the source at this quote in a new tab)

“The sponsor compared a reference scenario in which patients received SoC alone to a new drug scenario in which palovarotene was reimbursed as an add-on therapy to SoC, with palovarotene plus SoC assumed to capture 45% of the total market share by year 3, based on the sponsor’s internal estimates and expert opinion.” (opens the source at this quote in a new tab)